The SGX All Healthcare Index has generated a 0.7% total return in the January MTD, following a total return of 6.0% in the 2016 calendar year. This brings its five-year annualised total return to 11.2%.
The 10 best-performing constituents of the SGX All Healthcare index averaged MTD and one-year total returns of 9.8% and 22.2% respectively. These stocks outperformed the 10 largest Healthcare securities in Asia Pacific, which averaged MTD and one-year total returns of 0.4% and 2.7% respectively.
The five best-performing constituents of the SGX All Healthcare Index in the MTD are International Healthway Corporation (+32.0%), Pharmesis International (+25.0%), AsiaMedic (+10.4%), Talkmed Group (+6.9%) and iX Biopharma (+5.4%). They averaged a total return of 15.9% in the MTD and maintain an average dividend yield of 4.2%.
Singapore’s healthcare sector has a combined market value of about S$30 billion. According to the Global Industry Classification Standards (GICS®), the industry can be broken down into the following sub-segments – Health Care Equipment, Health Care Supplies, Health Care Services, Health Care Facilities, Biotechnology, and Pharmaceuticals.
The city-state also plays a key role in Asia’s healthcare industry, where multiple opportunities and challenges exist in the ongoing supply and demand for health services across the region. A recent
Market Update published on 6 January highlighted the performance of Singapore’s Healthcare Sector Leaders in 2016.
SGX Healthcare Index
The SGX All Healthcare Index comprises stocks that report at least half their revenues from healthcare in the last financial year, as well as REITs with investments in healthcare facilities. The Index, which is free-float and market capitalisation-weighted, consists of 27 constituents with a total market capitalisation of S$32.5 billion. The weightings of index components are capped at a maximum 10% at each periodical rebalance, so that it is better diversified across a range of stocks. More information on the historical performance and schematics of the Index can be found
here.
The SGX All Healthcare Index has generated a 0.7% total return in the January month-to-date, following a total return of 6.0% in the 2016 calendar year. This brings its five-year annualised total return to 11.2%.
The 10 best-performing constituents of the SGX All Healthcare index averaged MTD and one-year total returns of 9.8% and 22.2% respectively, maintaining a dividend yield of 3.5%. These stocks outperformed the 10 largest Healthcare securities in Asia Pacific, which averaged MTD and one-year total returns of 0.4% and 2.7% respectively.
These 10 largest Healthcare securities in Asia Pacific maintain a dividend yield of 1.6%.
The 10 largest Healthcare securities in Asia Pacific are listed in Sydney, Mumbai and Shanghai, with seven of the 10 in Tokyo. These 10 stocks have a market capitalisation of S$327 billion.
The five best-performing constituents of the SGX All Healthcare Index in the MTD were International Healthway Corporation (+32.0%), Pharmesis International (+25.0%), AsiaMedic (+10.4%), Talkmed Group (+6.9%) and iX Biopharma (+5.4%). They averaged a total return of 15.9% in the MTD and maintain an average dividend yield of 4.2%.
The table below details the 10 best
performers of the SGX All Healthcare Index, sorted by MTD total returns. Click on each stock to visit its profile page on SGX StockFacts.
| Name |
SGX Code |
Market Cap in S$M |
Total Return MTD % |
Total Return 1 Yr % |
Total Return 3 Yrs % |
P/E |
P/B |
ROE % |
Dvd Ind Yld % |
GICS® Sub Industry Name |
| Intl Healthway Corp |
5WA |
111 |
32.0 |
-25.0 |
-80.0 |
N/A |
0.5 |
-5.5 |
N/A |
Health Care Facilities |
| Pharmesis Intl |
BFK |
12 |
25.0 |
25.0 |
13.6 |
574.6 |
0.6 |
-0.1 |
N/A |
Pharmaceuticals |
| AsiaMedic |
505 |
30 |
10.4 |
13.8 |
-26.0 |
N/A |
1.7 |
-15.7 |
N/A |
Health Care Services |
| Talkmed Grp |
5G3 |
710 |
6.9 |
18.8 |
N/A |
19.3 |
13.3 |
73.4 |
4.2 |
Health Care Services |
| iX Biopharma |
42C |
189 |
5.4 |
-36.4 |
N/A |
N/A |
4.7 |
-31.8 |
N/A |
Pharmaceuticals |
| Medtecs Intl Corp |
546 |
26 |
4.3 |
9.1 |
-25.0 |
25.8 |
0.3 |
1.2 |
N/A |
Health Care Supplies |
| Raffles Medical Grp |
BSL |
2587 |
4.2 |
14.6 |
51.7 |
36.0 |
4.0 |
11.6 |
1.3 |
Health Care Facilities |
| Singapore Medical Grp |
5OT |
126 |
3.4 |
177.8 |
240.9 |
172.8 |
11.4 |
6.9 |
N/A |
Health Care Services |
| Parkway Life REIT |
C2PU |
1440 |
3.4 |
17.9 |
21.5 |
21.3 |
1.4 |
6.6 |
5.0 |
Health Care REITs |
| Healthway Medical Corp |
5NG |
93 |
3.0 |
6.3 |
-50.7 |
N/A |
0.5 |
-0.1 |
N/A |
Health Care Services |
| Average |
|
|
9.8 |
22.2 |
18.2 |
141.6 |
3.8 |
4.7 |
3.5 |
|
Source: SGX, Bloomberg & SGX StockFacts (data as of 17 January 2017)
The table below details the 10 largest healthcare stocks in Asia Pacific, sorted by market capitalisation.
| Name |
Exchange |
Market Cap in S$Bln |
Total Return MTD % |
Total Return 1 Yr % |
P/E |
P/B |
ROE % |
Dvd Ind Yld % |
| CSL |
ASX |
48.8 |
2.2 |
7.0 |
28.1 |
13.4 |
46.8 |
1.7 |
| Takeda Pharmaceutical Co |
TSE |
47.2 |
-0.4 |
-10.3 |
25.1 |
2.1 |
7.6 |
3.8 |
| Astellas Pharma Inc |
TSE |
42.1 |
-2.9 |
2.0 |
16.5 |
2.8 |
16.1 |
2.2 |
| Otsuka Holdings Co |
TSE |
39.5 |
12.0 |
47.4 |
43.4 |
2.0 |
4.4 |
1.8 |
| Sun Pharmaceutical Indus |
NSE |
32.5 |
1.1 |
-18.8 |
32.8 |
4.9 |
16.5 |
0.2 |
| Eisai Co |
TSE |
24.1 |
-2.3 |
-6.8 |
26.1 |
3.4 |
12.7 |
2.3 |
| Chugai Pharmaceutical Co |
TSE |
23.9 |
2.7 |
-7.6 |
33.2 |
3.0 |
9.1 |
1.5 |
| Hoya Corp |
TSE |
23.1 |
-2.7 |
7.2 |
22.6 |
4.2 |
16.9 |
1.6 |
| Shanghai Raas Blood Products Co |
SSE |
22.7 |
-5.0 |
-3.1 |
66.3 |
9.4 |
13.7 |
0.1 |
| Shionogi & Co |
TSE |
22.6 |
-1.1 |
10.5 |
23.7 |
3.6 |
15.3 |
1.2 |
| Average |
|
|
0.4 |
2.7 |
31.8 |
4.9 |
15.9 |
1.6 |
Source: SGX, Bloomberg & SGX StockFacts (data as of 17 January 2017)
Healthcare Trusts
Of the 32 REITs and six stapled trusts listed on Singapore Exchange, two are classified by GICS® as Health Care REITs. They are First Real Estate Investment Trust and Parkway Life Real Estate Investment Trust.
Health Care REITs are trusts engaged in the acquisition, development, ownership, leasing, management and operation of properties serving the health care industry, including hospitals, nursing homes, and assisted living properties.
RHT Health Trust, categorised by GICS® under the sub-segment of Health Care Facilities, is the first business trust listed on SGX with India-based healthcare assets. It has a portfolio of 12 Clinical Establishments, four Greenfield Clinical Establishments and two Operating Hospitals located across India.
First REIT, Parkway Life REIT and RHT Health Trust have a combined market capitalisation of S$3.2 billion. In the year thus far, they have averaged a dividend-inclusive total return of 1.9 % in the MTD, bringing their one-year and three-year total returns to 24.0% and 57.9% respectively.
Parkway Life REIT, First REIT, and RHT Health Trust have weightings of 9.76%, 9.85% and 8.93% respectively in the SGX All Healthcare Index.
The table below details the three Health Care trusts, sorted by market capitalisation. Click on each stock to visit its profile page on SGX StockFacts.
| Name |
SGX Code |
Market Cap in S$M |
Total Return MTD % |
Total Return 1 Yr % |
Total Return 3 Yrs % |
P/E |
P/B |
ROE % |
Dvd Ind Yld % |
GICS® Sub Industry Name |
| Parkway Life REIT |
C2PU |
1440 |
3.4 |
17.9 |
21.5 |
21.3 |
1.4 |
6.6 |
5.0 |
Health Care REITs |
| First REIT |
AW9U |
988 |
2.4 |
17.7 |
50.6 |
24.3 |
1.2 |
8.5 |
6.6 |
Health Care REITs |
| RHT Health Trust |
RF1U |
742 |
0.0 |
36.5 |
101.7 |
21.5 |
1.0 |
5.7 |
7.9 |
Health Care Facilities |
| Average |
|
|
1.9 |
24.0 |
57.9 |
22.4 |
1.2 |
6.9 |
6.5 |
|
Source: SGX, Bloomberg & SGX StockFacts (data as of 17 January 2017)
SGX My Gateway
SGX’s investor education portal with market, product and investment information and events. Sign up now at
sgx.com/mygateway to receive our investment updates and economic calendar.
This document is not intended for distribution to, or for use by or to be acted on by any person or entity located in any jurisdiction where such distribution, use or action would be contrary to applicable laws or regulations or would subject SGX to any registration or licensing requirement. This document is not an offer or solicitation to buy or sell, nor financial advice or recommendation for any investment product. This document has been published for general circulation only. It does not address the specific investment objectives, financial situation or particular needs of any person. Advice should be sought from a financial adviser regarding the suitability of any investment product before investing or adopting any investment strategies. Investment products are subject to significant investment risks, including the possible loss of the principal amount invested. Past performance of investment products is not indicative of their future performance. While SGX and its affiliates have taken reasonable care to ensure the accuracy and completeness of the information provided, they will not be liable for any loss or damage of any kind (whether direct, indirect or consequential losses or other economic loss of any kind) suffered due to any omission, error, inaccuracy, incompleteness, or otherwise, any reliance on such information. Neither SGX nor any of its affiliates shall be liable for the content of information provided by third parties. SGX and its affiliates may deal in investment products in the usual course of their business, and may be on the opposite side of any trades. SGX is an exempt financial adviser under the Financial Advisers Act (Cap. 110) of Singapore. The information in this document is subject to change without notice.
